AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the launch of its BCR/ABL1 Quant (RUO)* kit, a research tool utilizing multiplex real-time quantitative RT-PCR to provide simultaneous detection and quantification of BCR/ABL1 fusion transcripts (b2a2, b3a2, and e1a2), ABL1 (an endogenous control), and BCR/ABL1Quant Norm (an exogenous control) in a single reaction. The kit is based on TaqMan® technology and is compatible with ABI 7500 real-time systems or equivalent.
